Display options
Share it on

Front Neurol. 2017 Mar 21;8:88. doi: 10.3389/fneur.2017.00088. eCollection 2017.

Adenosine A.

Frontiers in neurology

Su-Bing Yin, Xiao-Guang Zhang, Shuang Chen, Wen-Ting Yang, Xia-Wei Zheng, Guo-Qing Zheng

Affiliations

  1. Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University , Wenzhou , China.

PMID: 28377741 PMCID: PMC5359221 DOI: 10.3389/fneur.2017.00088

Abstract

l-3,4-Dihydroxyphenylalanine (l-DOPA) remains the primary pharmacological agent for the symptomatic treatment of Parkinson's disease (PD). However, the development of l-DOPA-induced dyskinesia (LID) limits the long-term use of l-DOPA for PD patients. Some data have reported that adenosine A

Keywords: Parkinson’s disease; adenosine A2A receptor; dyskinesia; glutamic acid decarboxylase; striatum

References

  1. Eur J Neurosci. 2000 Mar;12(3):1096-104 - PubMed
  2. J Neurosci. 2000 Aug 15;20(16):5949-57 - PubMed
  3. Neurology. 2003 Aug 12;61(3):286-7 - PubMed
  4. J Neurochem. 1994 Apr;62(4):1375-81 - PubMed
  5. Neurology. 2011 May 24;76(21):1811-6 - PubMed
  6. Curr Neurol Neurosci Rep. 2012 Aug;12(4):376-85 - PubMed
  7. Trends Pharmacol Sci. 1998 Dec;19(12):500-5 - PubMed
  8. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6496-9 - PubMed
  9. Neurochem Res. 1991 Mar;16(3):215-26 - PubMed
  10. Int Rev Neurobiol. 2014;119:117-26 - PubMed
  11. Prog Neuropsychopharmacol Biol Psychiatry. 1993 Nov;17(6):887-903 - PubMed
  12. N Engl J Med. 2013 Feb 14;368(7):610-22 - PubMed
  13. Int Rev Neurobiol. 2014;119:127-50 - PubMed
  14. Life Sci. 2005 Nov 12;77(26):3259-67 - PubMed
  15. J Neurosci. 1993 Dec;13(12):5402-6 - PubMed
  16. J Neurosci. 2000 Aug 1;20(15):5848-52 - PubMed
  17. J Neural Transm (Vienna). 2011 Dec;118(12):1661-90 - PubMed
  18. J Neurol Sci. 2008 Mar 15;266(1-2):204-15 - PubMed
  19. J Pharmacol Exp Ther. 2011 Jun;337(3):755-65 - PubMed
  20. Brain Res. 1992 Mar 27;576(1):68-79 - PubMed
  21. Brain Res. 1988 May 3;447(2):346-52 - PubMed
  22. Neurosci Lett. 2003 Dec 11;352(3):167-70 - PubMed
  23. Neurobiol Dis. 2012 Jan;45(1):573-82 - PubMed
  24. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1970-5 - PubMed
  25. Synapse. 2002 Jun 1;44(3):166-74 - PubMed
  26. Exp Brain Res. 1989;77(3):611-20 - PubMed
  27. J Neurosci. 1991 Sep;11(9):2725-31 - PubMed
  28. Brain Res. 2005 May 24;1044(2):266-71 - PubMed
  29. Pharmacol Rev. 2013 Jan 10;65(1):171-222 - PubMed
  30. Mov Disord. 2005 Feb;20(2):190-9 - PubMed
  31. Exp Neurol. 2003 Nov;184(1):285-94 - PubMed
  32. Eur J Neurosci. 1998 Aug;10(8):2694-706 - PubMed
  33. Trends Neurosci. 2006 Nov;29(11):647-54 - PubMed
  34. J Neurochem. 1991 Feb;56(2):720-3 - PubMed
  35. Exp Neurol. 2010 Oct;225(2):384-90 - PubMed
  36. Prog Neurobiol. 2007 Dec;83(5):293-309 - PubMed
  37. Discov Med. 2013 Jan;15(80):61-6 - PubMed
  38. Cereb Cortex. 2001 Sep;11(9):806-15 - PubMed
  39. Nature. 1977 Apr 28;266(5605):847-8 - PubMed
  40. Brain Res Mol Brain Res. 1996 Jul;39(1-2):237-40 - PubMed
  41. Neuroscience. 2005;132(3):833-42 - PubMed
  42. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2115-9 - PubMed
  43. Brain Res. 2006 Dec 6;1123(1):196-200 - PubMed
  44. Physiol Behav. 2007 Sep 10;92(1-2):210-7 - PubMed
  45. J Biol Chem. 1999 Dec 24;274(52):37200-9 - PubMed
  46. Neuroscience. 2004;123(1):31-42 - PubMed
  47. J Neurochem. 1993 Jun;60(6):2334-7 - PubMed
  48. Glia. 2013 Oct;61(10):1645-58 - PubMed
  49. Neuroscience. 2015 Sep 10;303:586-94 - PubMed
  50. Trends Neurosci. 1997 Oct;20(10):482-7 - PubMed
  51. J Neurochem. 1993 Feb;60(2):714-20 - PubMed
  52. Brain Res. 1986 Nov 19;398(1):148-56 - PubMed
  53. Neuropharmacology. 2000 Apr 3;39(6):1004-15 - PubMed
  54. Neuroscience. 2009 Nov 10;163(4):1171-80 - PubMed
  55. Neuron. 1991 Jul;7(1):91-100 - PubMed
  56. Synapse. 1996 Feb;22(2):132-8 - PubMed
  57. Eur J Neurosci. 2003 Nov;18(9):2563-72 - PubMed
  58. J Neurochem. 1994 Mar;62(3):960-6 - PubMed
  59. PLoS One. 2011 Feb 28;6(2):e17338 - PubMed

Publication Types